FY2017 Earnings Estimate for DaVita HealthCare Partners Inc. Issued By William Blair (DVA)

DaVita HealthCare Partners Inc. (NYSE:DVA) – Analysts at William Blair cut their FY2017 earnings per share estimates for shares of DaVita HealthCare Partners in a research note issued on Monday. William Blair analyst M. Kaczor now anticipates that the company will earn $3.42 per share for the year, down from their previous estimate of $3.51. William Blair also issued estimates for DaVita HealthCare Partners’ Q4 2017 earnings at $0.89 EPS, Q1 2018 earnings at $0.80 EPS, Q2 2018 earnings at $0.94 EPS, Q3 2018 earnings at $0.95 EPS, Q4 2018 earnings at $0.90 EPS and FY2018 earnings at $3.60 EPS.

DaVita HealthCare Partners (NYSE:DVA) last released its quarterly earnings data on Tuesday, November 7th. The company reported $0.81 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.94 by ($0.13). DaVita HealthCare Partners had a return on equity of 13.31% and a net margin of 3.40%. The firm had revenue of $3.92 billion during the quarter, compared to analyst estimates of $3.91 billion. During the same period last year, the business earned $0.95 EPS. The firm’s revenue was up 5.2% on a year-over-year basis.

TRADEMARK VIOLATION NOTICE: This report was originally reported by Week Herald and is the sole property of of Week Herald. If you are reading this report on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this report can be viewed at https://weekherald.com/2017/11/15/fy2017-earnings-estimate-for-davita-healthcare-partners-inc-issued-by-william-blair-dva.html.

Other equities analysts have also issued research reports about the stock. TheStreet lowered shares of DaVita HealthCare Partners from a “b” rating to a “c+” rating in a research report on Wednesday, August 2nd. Zacks Investment Research upgraded shares of DaVita HealthCare Partners from a “sell” rating to a “hold” rating in a research report on Thursday, August 3rd. Jefferies Group LLC reiterated a “hold” rating and issued a $70.00 target price on shares of DaVita HealthCare Partners in a research report on Thursday, August 3rd. Royal Bank Of Canada reiterated a “hold” rating and issued a $64.00 target price on shares of DaVita HealthCare Partners in a research report on Wednesday, September 6th. Finally, KeyCorp reiterated a “hold” rating on shares of DaVita HealthCare Partners in a research report on Tuesday, October 10th. Four analysts have rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $63.00.

DaVita HealthCare Partners (NYSE DVA) opened at $54.66 on Tuesday. The stock has a market cap of $10,407.74, a PE ratio of 15.71, a P/E/G ratio of 11.05 and a beta of 0.98. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.40 and a quick ratio of 1.35. DaVita HealthCare Partners has a 12-month low of $52.51 and a 12-month high of $70.16.

DaVita HealthCare Partners declared that its board has authorized a stock buyback plan on Tuesday, October 10th that allows the company to buyback $1.50 billion in shares. This buyback authorization allows the company to buy shares of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its stock is undervalued.

Several large investors have recently bought and sold shares of the company. Accident Compensation Corp boosted its position in shares of DaVita HealthCare Partners by 106.3% during the 3rd quarter. Accident Compensation Corp now owns 31,150 shares of the company’s stock valued at $1,850,000 after purchasing an additional 16,050 shares in the last quarter. Schroder Investment Management Group boosted its position in shares of DaVita HealthCare Partners by 769.0% during the 3rd quarter. Schroder Investment Management Group now owns 434,191 shares of the company’s stock valued at $25,387,000 after purchasing an additional 384,224 shares in the last quarter. Hikari Power Ltd boosted its position in shares of DaVita HealthCare Partners by 8.1% during the 3rd quarter. Hikari Power Ltd now owns 312,300 shares of the company’s stock valued at $18,547,000 after purchasing an additional 23,400 shares in the last quarter. Oak Associates Ltd. OH boosted its position in shares of DaVita HealthCare Partners by 3.8% during the 3rd quarter. Oak Associates Ltd. OH now owns 192,185 shares of the company’s stock valued at $11,414,000 after purchasing an additional 6,990 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in shares of DaVita HealthCare Partners by 4.4% during the 3rd quarter. Rhumbline Advisers now owns 321,155 shares of the company’s stock valued at $19,073,000 after purchasing an additional 13,471 shares in the last quarter. Institutional investors own 84.73% of the company’s stock.

DaVita HealthCare Partners Company Profile

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Earnings History and Estimates for DaVita HealthCare Partners (NYSE:DVA)

Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply